IRVINE, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that it has received a Notice of Issuance for an additional compound for cardiovascular treatments. This patent issuance further exemplifies the Company’s plan to develop a broad platform of intellectual property involving atheroma stabilization and reduction, lipid modulation and other metabolic diseases. This issuance continues efforts by the Company and its patent counsel in pursuit of numerous patents covering the systemic delivery of naturally occurring bile acids, bile acid synthetics, analogs and conjugates.
Help employers find you! Check out all the jobs and post your resume.
